A First-in-human, Multicenter, Open-label, Phase 1 Study in Patients With Advanced Solid Malignancies to Evaluate the Safety of Intravenously Administered ATOR-1017

The aim of the study is to assess the safety and tolerability of increasing doses of ATOR-1017 when administered as repeated intravenous infusions to patients with advanced and/or refractory solid malignancies.

开始日期2019-12-03

申办/合作机构

Alligator Bioscience AB

100 项与 ATOR-1017 相关的临床结果

登录后查看更多信息

100 项与 ATOR-1017 相关的转化医学

登录后查看更多信息

100 项与 ATOR-1017 相关的专利（医药）

登录后查看更多信息

项与 ATOR-1017 相关的文献（医药）

2025-01-01·Journal for ImmunoTherapy of Cancer

First-in-human, multicenter, open-label, phase I study of ATOR-1017 (evunzekibart), a 4-1BB antibody, in patients with advanced solid malignancies

Article

作者: Enell Smith, Karin ; Hahn, Amanda ; Carneiro, Ana ; Ambarkhane, Sumeet ; Ellmark, Peter ; Yachnin, Jeffrey ; Ullenhag, Gustav J ; Schultz, Lena

Background:

ATOR-1017 (evunzekibart) is a human agonistic immunoglobulin G4 antibody targeting the costimulatory receptor 4-1BB (CD137). ATOR-1017 activates T cells and natural killer cells in the tumor environment, leading to immune-mediated tumor cell death.

Methods:

In this first-in-human, multicenter, phase I study, ATOR-1017 was administered intravenously every 21 days as a monotherapy to patients with advanced, unresectable solid tumors having received multiple standard-of-care treatments. The study used single patient cohorts for rapid dose escalation up to 40 mg; thereafter a modified 3+3 design up to 900 mg. Escalating doses were given until disease progression, unacceptable toxicity, or withdrawal of consent. The primary objective of the study included determination of the maximum tolerated dose (MTD) via assessment of adverse events and dose-limiting toxicities (DLTs). Secondary objectives included determination of the pharmacokinetics, immunogenicity and clinical efficacy assessed with CT scans using immune Response Evaluation Criteria in Solid Tumors. Exploratory objectives included pharmacodynamic (PD) assessment of immune system biomarkers.

Results:

Of the 27 patients screened, 25 received treatment with ATOR-1017. The median time on study was 13.1 weeks (range 4.3–92.3). The MTD of ATOR-1017 was not reached. Treatment-related adverse events (TRAEs) were reported in 13 (52%) of 25 patients; most common (≥10%) were fatigue (n=4 (16.0%) patients) and neutropenia (n=3 (12.0%) patients). Five patients experienced a severe (≥ grade 3) TRAE; neutropenia (n=2), febrile neutropenia (n=1), chest pain (n=1), increased liver enzymes (n=1), and leukopenia and thrombocytopenia (n=1). No patients discontinued due to TRAEs and no DLTs were observed. Pharmacokinetic data demonstrated approximate dose-proportional kinetics. Dose-dependent increases in PD biomarkers, including soluble 4-1BB, are indicative of target-mediated biological activity. Best response was stable disease in 13 out of 25 patients (52%), maintained for 6 months or longer in six patients (24%).

Conclusions:

Treatment with ATOR-1017 was safe and well tolerated at all dose levels and demonstrated biological activity. Furthermore, almost one-third of patients experienced long-lasting stable disease in this heavily pretreated population. The encouraging safety and preliminary efficacy data warrant further clinical development of ATOR-1017, possibly in combination with other anticancer agents.

2023-12-01·Cancer immunology, immunotherapy : CII

ATOR-1017 (evunzekibart), an Fc-gamma receptor conditional 4-1BB agonist designed for optimal safety and efficacy, activates exhausted T cells in combination with anti-PD-1

Article

作者: Barchan, Karin ; Säll, Anna ; Varas, Laura ; Enell Smith, Karin ; von Schantz, Laura ; Rose, Nadia ; Ellmark, Peter ; Rosén, Anna ; Schultz, Lena ; Håkansson, Maria ; Nilsson, Anneli ; Fritzell, Sara

Abstract:

Background:

4-1BB (CD137) is a co-stimulatory receptor highly expressed on tumor reactive effector T cells and NK cells, which upon stimulation prolongs persistence of tumor reactive effector T and NK cells within the tumor and induces long-lived memory T cells. 4-1BB agonistic antibodies have been shown to induce strong anti-tumor effects that synergize with immune checkpoint inhibitors. The first generation of 4-1BB agonists was, however, hampered by dose-limiting toxicities resulting in suboptimal dose levels or poor agonistic activity.

Methods:

ATOR-1017 (evunzekibart), a second-generation Fc-gamma receptor conditional 4-1BB agonist in IgG4 format, was designed to overcome the limitations of the first generation of 4-1BB agonists, providing strong agonistic effect while minimizing systemic immune activation and risk of hepatoxicity. The epitope of ATOR-1017 was determined by X-ray crystallography, and the functional activity was assessed in vitro and in vivo as monotherapy or in combination with anti-PD1.

Results:

ATOR-1017 binds to a unique epitope on 4-1BB enabling ATOR-1017 to activate T cells, including cells with an exhausted phenotype, and NK cells, in a cross-linking dependent, FcγR-conditional, manner. This translated into a tumor-directed and potent anti-tumor therapeutic effect in vivo, which was further enhanced with anti-PD-1 treatment.

Conclusions:

These preclinical data demonstrate a strong safety profile of ATOR-1017, together with its potent therapeutic effect as monotherapy and in combination with anti-PD1, supporting further clinical development of ATOR-1017.

项与 ATOR-1017 相关的新闻（医药）

2025-01-31

·Business Wire

CD137 Antibodies Market Research 2024-2027: $400 Million Opportunity In Initial 24 Months Of Launch, 80 Drugs in Clinical Trials, 7 Drugs in Phase II - ResearchAndMarkets.com

DUBLIN--( BUSINESS WIRE )--The "CD137 Antibodies Clinical Trials & Market Opportunity Insight" report has been added to ResearchAndMarkets.com's offering. The market potential for effective CD137 antibodies is significant, considering the wide range of applications of CD137-targeted treatments in cancer. New and efficient treatment modalities are highly sought after, as the global market for cancer immunotherapy is expected to grow to many billions of dollars in the next several years. A sizeable portion of this market may be taken up by CD137-targeted treatments, especially if they show greater efficacy and can treat conditions where immunotherapies have not been very successful. CD137 Antibodies Clinical Trials & Market Opportunity Insight 2027 Report Highlights: Currently No Drug Commercially Available In Market More Than 80 Drugs In Clinical Trials Highest Clinical Trials Phase: Phase II (7 Drugs) CD137 Drugs Market Opportunity In Initial 24 Months Of Launch: > US$ 400 Million Global & Regional Trends (Clinical & Commercial) CD137 Inhibitors Clinical Trials Insight By Company, Country, Indication & Phase CD137 Therapeutic Approaches By Antibodies Classification Role Of CD137 & Clinical Progress By Indication CD137, also known as 4-1BB, has emerged as a promising target for cancer immunotherapy in recent years. The potential of CD137-targeted therapies lies in their ability to stimulate and expand cytotoxic T cells leading to improved tumor cell killing and long-lasting immune memory. As a result, the field has gained attention from researchers and pharmaceutical companies alike, with several research publications hinting at a promising future for this cancer therapeutic approach. Moreover, data emerging from early clinical trials have already begun demonstrating therapeutic benefits, providing real-time validation of CD137-targeted drug development. With no licensed medications currently on the market, CD137-targeted therapies are still in their infancy. Nonetheless, there is an abundance of candidates in the pipeline in different phases of clinical development, with phase 2 being the highest. Several major pharmaceutical companies and biotech firms, including BioNTech, Genmab, Adagene, and Shanghai Henlius Biotech, are actively pursuing drug development programs after recognizing the potential of this target. This presents a significant opportunity for both established players and newcomers in the field of immuno-oncology. The ability of CD137-targeted treatments to get past some of the drawbacks of existing immunotherapies, like immune checkpoint inhibitors, is one of their main advantages. Although checkpoint inhibitors have fundamentally altered the way that cancer is treated, only a small percentage of patients and cancer types respond well to them. The range of individuals who can benefit from immunotherapy may be increased by CD137 agonists, which may enhance or supplement the effectiveness of these currently available treatments. The most advanced CD137-targeted therapies in clinical development are agonistic antibodies. The intended effect of these compounds is to stimulate T cell survival, proliferation, and effector activities via activating CD137 signaling. Regarding anti-tumor effectiveness and safety characteristics, early clinical trials have produced encouraging results. YH004, ADG106, ADG206, and ATOR-1017 are a few CD137 agonistic antibodies that are now undergoing clinical trials. There have been challenges, nevertheless, such as dose-limiting hepatotoxicity seen in certain candidates. Due to this, other strategies are being investigated that might provide better safety and efficacy profiles, such as bispecific antibodies and tailored ligands. Combining CD137-targeted therapies with other immunomodulatory drugs is one highly intriguing area of investigation. CD137 agonists have been shown to have synergistic benefits when paired with checkpoint inhibitors, chemotherapy, targeted therapy, or even radiation therapy, according to preclinical research and early phase clinical evidence. These combination approaches may result in more potent and more persistent anti-tumor responses, which would fulfill the unmet demand for efficient treatments for malignancies that are challenging to treat. Furthermore, the versatility of CD137 as a target extends beyond oncology. Recent studies point to possible uses in transplantation, autoimmune diseases, inflammatory disorders, and infectious diseases. This wide-ranging therapeutic potential could open up additional market opportunities for drug developers, willing to explore these indications. Despite the promising outlook, several challenges need to be addressed in the development of CD137-targeted therapies. These include optimizing dosing regimens to balance efficacy and safety, identifying predictive biomarkers for patient section, and developing strategies to overcome potential resistance mechanisms. Overcoming these hurdles will be crucial for the successful translation of CD137-targeted therapies from bench to bedside. In conclusion, CD137-targeted therapies represent a significant opportunity to transform treatment of cancer and various other diseases involving the immune system. The increasing comprehension of CD137 biology, in conjunction with developments in antibody engineering and combination strategies, offers a robust basis for novelty in this domain. CD137-targeted therapies have the potential to fill a significant gap in the medical community and gain a significant portion of the cancer immunotherapies market, which presents a strong case for development and innovation. Key Topics Covered: 1. Brief Introduction To CD137 1.1 Clinical Overview 1.2 Biological History Of CD137 1.3 CD137 Hosting An Era Of Agonists Over Antagonists 1.4 Bi-Directional Signaling In CD137 2. Global CD137 Antibody Market Outlook 2.1 Current Research & Market Scenario 2.2 Future Commercialization Opportunities 3. CD137 Antibody Clinical Developments by Regions 3.1 China 3.2 US 3.3 South Korea 3.4 Europe 3.5 Australia 4. Role Of CD137 & Clinical Progress By Indication 4.1 Cancer 4.1.1 Leukemia 4.1.2 Lymphoma 4.1.3 Lung Cancer 4.1.4 Melanoma 4.1.5 Breast Cancer 4.1.6 Colorectal Cancer 4.2 Autoimmune & Inflammatory Diseases 4.3 Microbial Infections 4.3.1 Viral Infections 4.3.2 Bacterial infections 5. Global CD137 Antibodies Clinical Trials Overview 5.1 By Company 5.2 By Country 5.3 By Indication 5.4 By Phase 5.5 By Patient Segment 6. CD137 Inhibitors Clinical Trials Insight By Company, Country, Indication & Phase 6.1 Research 6.2 Preclinical 6.3 Phase I 6.4 Phase I/II 6.5 Phase II 7. CD137 Targeting Proprietary Technology Platforms By Companies 8. CD137 Therapeutic Approaches By Antibodies Classification 8.1 Monoclonal Antibody Based Strategies 8.2 Bispecific Antibody Centered Approaches 8.3 Trispecific Antibody Established Strategies 8.4 Tetraspecific Antibody Strategies 9. Combination Therapies With CD137 Antibodies 10. Competitive Landscape 10.1 ABL Bio 10.2 Adagene 10.3 Alligator Bioscience 10.4 BeiGene 10.5 Bicycle Therapeutics 10.6 BioNTech 10.7 Biotheus 10.8 Crescendo Biologics 10.9 Eutilex 10.10 F-star Therapeutics 10.11 Genmab 10.12 I-MAB Biopharma 10.13 Lyvgen Biopharma 10.14 OriCell Therapeutics 10.15 Pieris Pharmaceuticals 10.16 Shanghai Henlius Biotech 10.17 Sichuan Baili Pharmaceutical 10.18 SystImmune For more information about this report visit https://www.researchandmarkets.com/r/cb9n0w About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

免疫疗法临床2期放射疗法

2024-09-18

·Business Wire

CD137 Antibodies Clinical Trials & Market Opportunity Insight 2027 - Over 80 Drugs In Clinical Trials - ResearchAndMarkets.com

DUBLIN--( BUSINESS WIRE )--The "CD137 Antibodies Clinical Trials & Market Opportunity Insight 2027" report has been added to ResearchAndMarkets.com's offering. CD137, also known as 4-1BB, has emerged as a promising target for cancer immunotherapy in recent years. The potential of CD137-targeted therapies lies in their ability to stimulate and expand cytotoxic T cells leading to improved tumor cell killing and long-lasting immune memory. As a result, the field has gained attention from researchers and pharmaceutical companies alike, with several research publications hinting at a promising future for this cancer therapeutic approach. Moreover, data emerging from early clinical trials have already begun demonstrating therapeutic benefits, providing real-time validation of CD137-targeted drug development. With no licensed medications currently on the market, CD137-targeted therapies are still in their infancy. Nonetheless, there is an abundance of candidates in the pipeline in different phases of clinical development, with phase 2 being the highest. Several major pharmaceutical companies and biotech firms, including BioNTech, Genmab, Adagene, and Shanghai Henlius Biotech, are actively pursuing drug development programs after recognizing the potential of this target. This presents a significant opportunity for both established players and newcomers in the field of immuno-oncology. The ability of CD137-targeted treatments to get past some of the drawbacks of existing immunotherapies, like immune checkpoint inhibitors, is one of their main advantages. Although checkpoint inhibitors have fundamentally altered the way that cancer is treated, only a small percentage of patients and cancer types respond well to them. The range of individuals who can benefit from immunotherapy may be increased by CD137 agonists, which may enhance or supplement the effectiveness of these currently available treatments. The most advanced CD137-targeted therapies in clinical development are agonistic antibodies. The intended effect of these compounds is to stimulate T cell survival, proliferation, and effector activities via activating CD137 signaling. Regarding anti-tumor effectiveness and safety characteristics, early clinical trials have produced encouraging results. YH004, ADG106, ADG206, and ATOR-1017 are a few CD137 agonistic antibodies that are now undergoing clinical trials. There have been challenges, nevertheless, such as dose-limiting hepatotoxicity seen in certain candidates. Due to this, other strategies are being investigated that might provide better safety and efficacy profiles, such as bispecific antibodies and tailored ligands. Combining CD137-targeted therapies with other immunomodulatory drugs is one highly intriguing area of investigation. CD137 agonists have been shown to have synergistic benefits when paired with checkpoint inhibitors, chemotherapy, targeted therapy, or even radiation therapy, according to preclinical research and early phase clinical evidence. These combination approaches may result in more potent and more persistent anti-tumor responses, which would fulfill the unmet demand for efficient treatments for malignancies that are challenging to treat. The market potential for effective CD137 antibodies is significant, considering the wide range of applications of CD137-targeted treatments in cancer. New and efficient treatment modalities are highly sought after, as the global market for cancer immunotherapy is expected to grow to many billions of dollars in the next several years. A sizeable portion of this market may be taken up by CD137-targeted treatments, especially if they show greater efficacy and can treat conditions where immunotherapies have not been very successful. Furthermore, the versatility of CD137 as a target extends beyond oncology. Recent studies point to possible uses in transplantation, autoimmune diseases, inflammatory disorders, and infectious diseases. This wide-ranging therapeutic potential could open up additional market opportunities for drug developers, willing to explore these indications. Despite the promising outlook, several challenges need to be addressed in the development of CD137-targeted therapies. These include optimizing dosing regimens to balance efficacy and safety, identifying predictive biomarkers for patient section, and developing strategies to overcome potential resistance mechanisms. Overcoming these hurdles will be crucial for the successful translation of CD137-targeted therapies from bench to bedside. In conclusion, CD137-targeted therapies represent a significant opportunity to transform treatment of cancer and various other diseases involving the immune system. The increasing comprehension of CD137 biology, in conjunction with developments in antibody engineering and combination strategies, offers a robust basis for novelty in this domain. CD137-targeted therapies have the potential to fill a significant gap in the medical community and gain a significant portion of the cancer immunotherapies market, which presents a strong case for development and innovation. CD137 Antibodies Clinical Trials & Market Opportunity Insight 2027 Report Highlights: Currently No Drug Commercially Available In Market More Than 80 Drugs In Clinical Trials Highest Clinical Trials Phase: Phase II (7 Drugs) CD137 Drugs Market Opportunity In Initial 24 Months Of Launch: > US$ 400 Million Global & Regional Trends (Clinical & Commercial) CD137 Inhibitors Clinical Trials Insight By Company, Country, Indication & Phase CD137 Therapeutic Approaches By Antibodies Classification Role Of CD137 & Clinical Progress By Indication Key Topics Covered: 1. Brief Introduction To CD137 1.1 Clinical Overview 1.2 Biological History Of CD137 1.3 CD137 Hosting An Era Of Agonists Over Antagonists 1.4 Bi-Directional Signaling In CD137 2. Global CD137 Antibody Market Outlook 2.1 Current Research & Market Scenario 2.2 Future Commercialization Opportunities 3. CD137 Antibody Clinical Developments by Regions 3.1 China 3.2 US 3.3 South Korea 3.4 Europe 3.5 Australia 4. Role Of CD137 & Clinical Progress By Indication 4.1 Cancer 4.1.1 Leukemia 4.1.2 Lymphoma 4.1.3 Lung Cancer 4.1.4 Melanoma 4.1.5 Breast Cancer 4.1.6 Colorectal Cancer 4.2 Autoimmune & Inflammatory Diseases 4.3 Microbial Infections 4.3.1 Viral Infections 4.3.2 Bacterial infections 5. Global CD137 Antibodies Clinical Trials Overview 5.1 By Company 5.2 By Country 5.3 By Indication 5.4 By Phase 5.5 By Patient Segment 6. CD137 Inhibitors Clinical Trials Insight By Company, Country, Indication & Phase 6.1 Research 6.2 Preclinical 6.3 Phase I 6.4 Phase I/II 6.5 Phase II 7. CD137 Targeting Proprietary Technology Platforms By Companies 8. CD137 Therapeutic Approaches By Antibodies Classification 8.1 Monoclonal Antibody Based Strategies 8.2 Bispecific Antibody Centered Approaches 8.3 Trispecific Antibody Established Strategies 8.4 Tetraspecific Antibody Strategies 9. Combination Therapies With CD137 Antibodies 10. Competitive Landscape ABL Bio Adagene Alligator Bioscience BeiGene Bicycle Therapeutics BioNTech Biotheus Crescendo Biologics Eutilex F-star Therapeutics Genmab I-MAB Biopharma Lyvgen Biopharma OriCell Therapeutics Pieris Pharmaceuticals Shanghai Henlius Biotech Sichuan Baili Pharmaceutical SystImmune For more information about this report visit https://www.researchandmarkets.com/r/uh1uil About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

免疫疗法临床2期

2023-02-14

·PipelineReview

Alligator Bioscience & Aptevo Therapeutics Announce Dosing of First Patient with ALG.APV-527 in Phase 1 Clinical Trial

Trial to Evaluate Safety, Tolerability and Clinical Activity in Solid Tumors Expressing 5T4 LUND, Sweden and SEATTLE, WA, USA I February 13, 2023 I Alligator Bioscience AB ("Alligator") (Nasdaq Stockholm: ATORX) and Aptevo Therapeutics ("Aptevo") (NASDAQ:APVO) today announced the dosing of the first patient in the companies' Phase 1 trial evaluating ALG.APV-527 for the treatment of solid tumors expressing the tumor-associated antigen 5T4. ALG.APV-527 is a bispecific antibody with a tumor-directed 4-1BB agonistic effect and the ability to specifically stimulate antitumor-specific T cells and NK cells involved in tumor control. "We are very pleased to announce the initiation of a clinical trial to evaluate ALG.APV-527 in patients with solid tumors with high prevalence of 5T4. For Aptevo, the initiation of a second clinical program means we are now developing therapeutics to treat both solid tumors and hematological malignancies - a strategic win for our company," said Marvin White, President, and CEO of Aptevo. "ALG.APV-527 is a compelling candidate, as preclinical studies showed it has the potential to activate key immune cell populations within the tumor microenvironment while demonstrating a favorable safety profile. We look forward to sharing preliminary results, which we anticipate will be available in 2023." "The start of this Phase 1 first in human study is an important milestone in the development of ALG.APV-527 and demonstrates the growing strength and effectiveness of our partnership with Aptevo," said Søren Bregenholt, PhD, CEO of Alligator Bioscience . "It also marks Alligator's third asset currently in clinical development and we are particularly excited to evaluate its tumor-directed 4-1BB function with its promise of a broad therapeutic window and, alike ATOR-1017, highly differentiated safety and efficacy profile compared to the first generation 4-1BB agonists." The ALG.APV-527 Phase 1 trial is a multi-center, multi-cohort, open-label trial that will include six cohorts in a 3+3 design. The trial will be conducted at up to 10 sites in the U.S. among adult patients with multiple solid tumor types/histologies likely to express the 5T4 antigen, including (but not limited to) non-small cell lung cancer (NSCLC), gastric/gastro-esophageal cancer and head and neck cancer. ALG.APV-527 will be given intravenously once every two weeks. The trial will assess the safety and tolerability, pharmacokinetic, pharmacodynamic and preliminary anti-tumor activity of ALG.APV-527. About ALG.APV-527 ALG.APV-527 is a bispecific conditional 4-1BB agonist, only active upon simultaneous binding to 4-1BB and 5T4. This has the potential to be clinically important because 4-1BB has the ability to stimulate the immune cells (antitumor-specific T cells and NK cells) involved in tumor control, making 4-1BB a particularly compelling target for cancer immunotherapy. 5T4 is an oncofetal tumor associated antigen overexpressed on numerous solid tumors including non-small-cell lung carcinoma (NSCLC), breast, head and neck, cervical, renal, gastric, and colorectal cancer. Preclinical studies, highlighting the differentiated design of the molecule that minimizes systemic immune activation, allowing for highly efficacious tumor-specific responses as demonstrated by potent activity in preclinical models, were recently published in the peer-reviewed publication, Molecular Cancer Therapeutics , a journal of the American Association for Cancer Research (AACR). The full article is available via this link: ALG.APV-527 MCT 2022 manuscript . About Alligator Bioscience Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator's portfolio includes several promising drug candidates, with the CD40 agonist mitazalimab as its key asset. Furthermore, Alligator is co-developing ALG.APV-527 with Aptevo Therapeutics Inc., several undisclosed molecules based on its proprietary technology platform, Neo-X-Prime™, and novel drug candidates based on the RUBY™ bispecific platform with Orion Corporation. Out-licensed programs include AC101/HLX22, in Phase 2 development, by Shanghai Henlius Biotech Inc. and an undisclosed target to Biotheus Inc. Alligator Bioscience's shares are listed on Nasdaq Stockholm (ATORX) and is headquartered in Lund, Sweden. For more information, please visit alligatorbioscience.com . About Aptevo Therapeutics Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel bispecific immunotherapies for the treatment of cancer. Aptevo is seeking to improve treatment outcomes and transform the lives of cancer patients. For more information, please visit www.aptevotherapeutics.com . SOURCE: Aptevo Therapeutics

临床1期临床2期免疫疗法AACR会议

100 项与 ATOR-1017 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
晚期恶性实体瘤	临床1期	瑞典	Alligator Bioscience AB	2019-12-03

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04144842 (SITC2022) 人工标引	临床1期	晚期恶性实体瘤	25	ATOR-1017	淵憲獵鹹襯窪廠醖範鏇(顧餘鬱積製範憲襯夢膚) = 鏇餘齋鹽網鏇鏇夢選築壓衊範鹹網膚餘願廠蓋 (獵範蓋餘鹽鏇淵糧糧積 ) 更多	积极	2022-11-01
NCT04144842 (Corporate Publications) 人工标引	临床1期	肿瘤	2	ATOR-1017	襯衊簾窪餘窪齋構範願(獵獵衊積襯鏇觸獵簾選) = 積鏇鹽膚襯鬱襯鏇積鹹願衊糧獵簾築願糧淵獵 (鏇鏇襯構襯膚衊遞夢鏇 )	积极	2022-09-30
NCT04144842 (ASCO2022) 人工标引	临床1期	晚期恶性实体瘤	22	ATOR-1017	範膚憲鏇網廠獵遞構鏇(網衊齋遞醖襯簾艱鹹鹽) = 鹽膚觸餘糧積鑰觸衊齋獵憲構獵齋廠夢構鹹醖 (願簾遞齋淵淵願艱膚窪 ) 更多	积极	2022-06-02